TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

NCT05111366 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Adjuvant Therapy

Interventions

DRUG: TQB2450 injection
DRUG: Anlotinib hydrochloride capsules

Sponsor

Xianhai Mao

Collaborators

[object Object]